81 related articles for article (PubMed ID: 27086848)
1. Enhancing doxorubicin efficacy through inhibition of aspartate transaminase in triple-negative breast cancer cells.
Yang Y
Biochem Biophys Res Commun; 2016 May; 473(4):1295-1300. PubMed ID: 27086848
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of GOT1 sensitizes colorectal cancer cells to 5-fluorouracil.
Hong C; Zheng J; Li X
Cancer Chemother Pharmacol; 2017 Apr; 79(4):835-840. PubMed ID: 28314989
[TBL] [Abstract][Full Text] [Related]
3. Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin.
Zhang X; Bai W
Cancer Chemother Pharmacol; 2016 Sep; 78(3):655-9. PubMed ID: 27473325
[TBL] [Abstract][Full Text] [Related]
4. Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells.
Li ZL; Chen C; Yang Y; Wang C; Yang T; Yang X; Liu SC
Int J Clin Exp Pathol; 2015; 8(5):4378-87. PubMed ID: 26191129
[TBL] [Abstract][Full Text] [Related]
5. Aspulvinone O, a natural inhibitor of GOT1 suppresses pancreatic ductal adenocarcinoma cells growth by interfering glutamine metabolism.
Sun W; Luan S; Qi C; Tong Q; Yan S; Li H; Zhang Y
Cell Commun Signal; 2019 Aug; 17(1):111. PubMed ID: 31470862
[TBL] [Abstract][Full Text] [Related]
6. Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin.
Wang F; Yang Y
Breast Cancer Res Treat; 2014 Aug; 147(1):203-10. PubMed ID: 25085754
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin Doxorubicin in triple-negative breast cancer cells.
Gründker C; Wokoun U; Hellriegel M; Emons G
J Obstet Gynaecol Res; 2019 Jul; 45(7):1334-1342. PubMed ID: 31016845
[TBL] [Abstract][Full Text] [Related]
8. Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer.
Himmel LE; Lustberg MB; DeVries AC; Poi M; Chen CS; Kulp SK
Exp Toxicol Pathol; 2016 Oct; 68(9):505-515. PubMed ID: 27555377
[TBL] [Abstract][Full Text] [Related]
9. Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity.
Bamodu OA; Huang WC; Tzeng DT; Wu A; Wang LS; Yeh CT; Chao TY
Cancer Lett; 2015 Aug; 364(2):125-34. PubMed ID: 25976769
[TBL] [Abstract][Full Text] [Related]
10. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN
Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155
[TBL] [Abstract][Full Text] [Related]
11. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
12. Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance.
Robinson P; Kasembeli M; Bharadwaj U; Engineer N; Eckols KT; Tweardy DJ
Biomed Res Int; 2016; 2016():1959270. PubMed ID: 26981525
[TBL] [Abstract][Full Text] [Related]
13. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
14. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.
Chittaranjan S; Bortnik S; Dragowska WH; Xu J; Abeysundara N; Leung A; Go NE; DeVorkin L; Weppler SA; Gelmon K; Yapp DT; Bally MB; Gorski SM
Clin Cancer Res; 2014 Jun; 20(12):3159-73. PubMed ID: 24721646
[TBL] [Abstract][Full Text] [Related]
15. Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2.
Pandiella A; Morís F; Ocaña A; Núñez LE; Montero JC
Oncotarget; 2015 Oct; 6(32):32856-67. PubMed ID: 26439989
[TBL] [Abstract][Full Text] [Related]
16. Integration of photothermal therapy and synergistic chemotherapy by a porphyrin self-assembled micelle confers chemosensitivity in triple-negative breast cancer.
Su S; Ding Y; Li Y; Wu Y; Nie G
Biomaterials; 2016 Feb; 80():169-178. PubMed ID: 26708642
[TBL] [Abstract][Full Text] [Related]
17. Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer.
Srinivasan A; Thangavel C; Liu Y; Shoyele S; Den RB; Selvakumar P; Lakshmikuttyamma A
Mol Carcinog; 2016 May; 55(5):743-56. PubMed ID: 25968914
[TBL] [Abstract][Full Text] [Related]
18. Piperine enhances the efficacy of TRAIL-based therapy for triple-negative breast cancer cells.
Abdelhamed S; Yokoyama S; Refaat A; Ogura K; Yagita H; Awale S; Saiki I
Anticancer Res; 2014 Apr; 34(4):1893-9. PubMed ID: 24692724
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
20. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
